Synthetic IL-2 cytokine-receptor pairs could improve T cell cancer therapies

Researchers at Stanford University suggest synthetic IL-2 cytokine-receptor pairs could improve T cell cancer immunotherapies -- including CAR T cell therapies -- by mitigating toxicities and off-target effects of IL-2 as an adjuvant.

Prior clinical data has shown

Read the full 379 word article

User Sign In